Authors
Latest:
Dr. Schlumberger Draws Conclusions From the SELECT Trial in Thyroid CancerMartin Schlumberger, MD, Institut Gustave Roussy, Villejuif Cedex, professor of oncology, University Paris-Sud, France, discusses the takeaway points for a community oncologist from the SELECT trial.
Latest:
Dr. van den Bent on Next Steps for ABT-414 in Brain CancerMartin J. van den Bent, MD, ‎Head Neuro-Oncology Unit at Erasmus MC Cancer Center, discusses what the next trials will be for ABT-414, anti-EGFR antibody-drug conjugate under exploration for patients with brain cancer.
Latest:
Dr. Weise Discusses the Future of Biosimilars in OncologyMartina Weise, MD, head of Division Licensing 2, and German CHMP member of the Federal Institute for Drugs and Medical Devices, discusses the future of biosimilars in oncology.
Latest:
Dr. Piccart on Personalized Care for Breast CancerMartine J. Piccart, MD, PhD, professor, Université Libre de Bruxelles, director, Medicine Department, Institut Jules Bordet, discusses personalized care for patients with breast cancer.
Latest:
Dr. Piccart Discusses Biomarkers in Early Breast CancerMartine J. Piccart, MD, PhD, professor, Université Libre de Bruxelles, director, Medicine Department, Institut Jules Bordet, discusses biomarkers in early breast cancer.
Latest:
Future Outlooks in the Treatment of Metastatic Colorectal CancerExperts discuss their vision for the future of colorectal cancer treatment and anticipated advancements in the field.
Latest:
Dr Fakih on OS Data for Sotorasib Plus Panitumumab in KRAS G12C+ mCRCMarwan G. Fakih, MD, discusses data for sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.
Latest:
Navigating mCRC: Treatment Options in the Third-Line SettingPanelists discuss their preferred treatment options for patients in the third-line setting of metastatic colorectal cancer (mCRC), focusing on regorafenib, trifluridine-tipiracil plus bevacizumab, and fruquintinib, and share insights on how patient and disease-specific factors influence the selection of the most appropriate regimen for each clinical scenario.
Latest:
Multiple Factors Contribute to Disparities in Health and Cancer OutcomesThe issue of disparities in cancer is multifactorial, as it can cover not only race, ethnic, and cultural issues, but also gender identification.
Latest:
As the Global Burden of Cancer Rises, Can Fellowship Training Adapt?As a fellowship director, Mary Chamberlin, MD, needed to adopt a new mind-set when training her fellows from low-income countries.
Latest:
Dr Taplin on Health Care Inequities in Prostate Cancer TreatmentMary-Ellen Taplin, MD, discusses strategies to mitigate health care inequities in prostate cancer.
Latest:
Filling a Gap in Posttransplant Care: The Transitional Transplant ClinicThe Long-Term Follow-Up (LTFU) Clinical Program at Seattle Cancer Care Alliance (SCCA) has expanded its scope of services to assist in the hands-on management of patients who develop complex conditions more than 100 days after their peripheral blood hematopoietic stem cell transplant procedure
Latest:
Mary Gullatte Discusses Nursing ShortagesMary Gullatte, the president of the Oncology Nursing Society, Discusses Nursing Shortages
Latest:
Dr. Hendrix on Metastatic Cells in MicroenvironmentsDr. Mary J. C. Hendrix from Northwestern University's Feinberg School of Medicine on Metastatic Tumor Cells in Microenvironments
Latest:
Dr. Fidler on Balancing Benefit of Novel Agents in EGFR Exon 20–Mutant NSCLC With ToxicitiesMary Jo J. Fidler, MD, discusses the potential for novel agents in EGFR exon 20–mutated non–small cell lung cancer.
Latest:
Dr. Fidler on the Potential Utility of ctDNA to Inform Treatment Escalation in Lung CancerMary Jo J. Fidler, MD, discusses the potential utility of circulating tumor DNA to inform treatment escalation in lung cancer.
Latest:
Initiative Seeks to Advance Molecular Understanding of Pancreatic CancerA partnership between the Pancreatic Cancer Action Network and Perthera, a self-described "concierge" for molecular diagnostic testing, is aiming to give patients with this hard-to-treat cancer the ability to determine the best course of treatment.
Latest:
Myriad CEO Discusses Reimbursement Hurdles in Molecular TestingMark C. Capone discusses the challenges and opportunities in molecular diagnostics, and what's ahead at Myriad Genetics.
Latest:
The Community Option: The Road Less TraveledAs we advance toward producing an integrated cancer model, the value of the practicing community oncologist has revealed itself to be an integral piece of the puzzle.
Latest:
Dr. Disis on the Rationale For Investigating PRGN-3005 With/Without Lymphodepletion in Ovarian CancerMary “Nora” Disis, MD, discusses the rationale for investigating the efficacy and optimal delivery of PRGN-3005 autologous UltraCAR T cells in patients with advanced stage platinum-resistant ovarian cancer.
Latest:
Mary Lou Woodford on CoC Accreditation ComplianceMary Lou Woodford, from the Cancer Resource Foundation, provides guidance on staying compliant with the new patient navigation accreditation standards from the American College of Surgeons Commission on Cancer.
Latest:
PrimeMD, a Pain Reporting Smartphone Application for Patients Undergoing Head and Neck RadiationA feasibility study of a smartphone application that patients undergoing radiation therapy for head and neck cancer can use to regularly report mucositis symptoms.
Latest:
Dr. Shafaee on the Value of BiosimilarsMaryam Nemati Shafaee, MD, assistant professor, Duncan Cancer Center, Lester & Sue Smith Breast Cancer, Baylor College of Medicine, discusses the value of biosimilars in oncology.
Latest:
Dr. Kwa on the TAILORx Trial in Breast CancerMaryann J. Kwa, MD, instructor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the results of the TAILORx trial in breast cancer.
